A Phase 4 interventional study of TEBOFORTAN in Mild Cognitive Impairment (MCI), sponsored by Fundació ACE Institut Català de Neurociències Aplicades. Status unknown at 1 site in Spain. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-02-15.
Sponsored by Fundació ACE Institut Català de Neurociències Aplicades · Phase 4, Interventional, and Treatment
Mild Cognitive Impairment (MCI) is the moderate impairment of a mental abilities to perform intellectual activities eg memory, calculation, communication... MCI is a disorder that can occur earlier than dementia such as Alzheimer's disease. It is believed that there are several factors involved such as inflammation and oxidative stress which is the production of reactive oxygen species that damage cells.
This clinical study tries to evaluate that a treatment already approved by the AEMPS, EGb 761® (Tebofortan), could reduce the levels of markers of inflammation and oxidation in the blood.
This treatment is based on a plant called Gingko Biloba. In the study, half of the participants would be administered EGb 761® during 24 months and the other half would not receive this treatment during 12 months and will received EGb 761® for the next 12 months.
3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.
This study's enrollment of 100 is above the median of 50 across 2,437 interventional studies indexed under Inflammation.
Browse Inflammation studies →Fundació ACE Institut Català de Neurociències Aplicades is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Treatment with EGb 761® (TEBOFORTAN 240 mg) during 24 months.
Drug: TEBOFORTAN
No Treatment during 12 months and treatment with EGb 761® (TEBOFORTAN 240 mg) for the next 12 months.
TEBOFORTAN 240 mg is administrated 1 tablet per day
Compare changes in blood marker levels of inflammation and oxidation
To compare the changes in the levels of blood markers of inflammation and oxidation between the baseline visit and the follow-up visits at 6 and 12 months between the study group (patients with mild cognitive impairment who receive treatment with 1 daily tablet of EGb 761® 240 mg orally) and the control group (patients with the same clinical characteristics without treatment with EGb 761®). Blood markers of inflammation and oxidation: in v0 (baseline), v1 (6 month), v2 (12 month). The panel of inflammation markers from Olink proteomics (https://www.olink.com/products/inflammation/) will be used with 92 proteins associated with inflammatory diseases and related biological processes. The blood samples of the participants will be collected in the Fundació ACE Nursing Unit and sent to Olink proteomics for further analysis
Time frame: Between the baseline visit and follow-up visits at 6 and 12 months. All procedures in each of the visits will be carried out in a maximum period of 30 days.
Compare scores on neuropsychiatric tests
A neuropsychological evaluation will be performed in v0, v2 and v4. The neuropsychological battery may be administered in person or telematically indistinctly. Fundació ACE Battery (N-BACE) (Alegret M et al., 2012, Alegret M et al., 2013).
Time frame: Between baseline visit and follow-up visit at 12 moths and follow-up visit at 24 months. All procedures in each of the visits will be carried out in a maximum period of 30 days.
Compare changes in cognitive test scores
Neurological evaluation will be performed in v0, v2 and v4. It consists of a structured anamnesis of the patient and an informant. Data on age, sex, educational level, medical history, including cardiovascular risk factors, and treatment received are collected. A complete neurological examination using the Spanish version of the Mini Mental State Examination test is administered. Hachinski ischemia scale, the Spanish version of the Neuropsychiatric Inventory Questionnaire, the Global Deterioration Scale, the Clinical Dementia Rating and the Blessed scale. follow-up visit between the study group and the control group
Time frame: Between baseline visit, follow-up visit at 12 moths and follow-up visit at 24 months. All procedures in each of the visits will be carried out in a maximum period of 30 days.
Obtain data of changes in blood marker levels of inflammation and oxidative stress and security data
Obtain data on levels of blood markers of inflammation and oxidative stress and safety for two years in the group receiving EGb761® during the first 12 month of the study and one year in the group control.Blood markers of inflammation and oxidation: in v0 (baseline), v1 (6 month), v2 (12 month), v3 (18 month), v4 (24 month) and in the Follow-up visit one month after the end of the treatment.
Time frame: Between v0 (baseline), v1 (6 month), v2 (12 month), v3 (18 month), v4 (24 month) and in the Follow-up visit one month after the end of the treatment. All procedures in each of the visits will be carried out ina maximum period of 30 days.
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació ACE Institut Català de Neurociències Aplicades